BR102021013516A2 - DIAGNOSIS OF ALZHEIMER VIA SALIVA USING THE LATERAL FLOW IMMUNOASSAY METHOD - Google Patents

Abstract

The present invention describes a new and inventive material for carrying out the diagnostic test for Alzheimer's via saliva using the lateral flow immunoassay method, the collection tube with an amount of buffer solution and the dropper being used to collect and pour the mixture. With the aim of determining whether or not the individual has the disease, detecting the beta-amyloid protein (beta-amyloid 42) with the anti-beta-amyloid antibody in the rapid test.

Description

DIAGNOSIS OF ALZHEIMER VIA SALIVA USING THE LATERAL FLOW IMMUNOASSAY METHOD Field of Invention

[01] Pharmaceutical product for Alzheimer's detection recommended for people over 60 years old, using a non-invasive method via saliva, where the individual spit into an open tube up to the filling line (Without bubbles, with the guidance not to drink water for 10 minutes before collection.Avoid eating, drinking, smoking, chewing gum, brushing teeth or washing your mouth 30 minutes before collection), rocking the capped tube for 5-10 seconds, collecting the liquid with the dropper to place inside the quick test in which the result comes out in up to 30 minutes indicating whether the person has alzheimer's or not even before showing symptoms, so that he can seek medical care.

Background of the Invention

[02] One of the main reasons for the production of the present invention is the use of the enzyme-linked immunosorbent assay (ELISA) method for the same objective, the detection of beta-amyloid protein, where it worked perfectly, which can have an understanding of the stage of disease, also having the possibility of diagnosis years before the first symptoms of alzheimer's disease.

[03] Based on information data from university researchers, the possibility of diagnosing Alzheimer's disease with the blood test was discovered, detecting the various plasma proteins associated with Alzheimer's to form a panel with biomarkers that represent a signature of Alzheimer's disease. blood disease. The test also allows doctors to identify which stage of Alzheimer's the patient is in, which allows closer monitoring of disease progression, facilitating early treatment.

[04] There are also other diagnostic methods such as personal history; Physical examination and laboratory tests: Dementia symptoms can be due to a number of other medical causes, such as vitamin deficiencies, infection, metabolic disturbances and side effects of medications, conditions that are often easily treated. Therefore, an initial step in the diagnosis of Alzheimer's is to exclude these causes through physical examination and blood and urine tests; Radiological Examination: Standard X-rays may be taken and people who smoke will usually be asked to have a chest X-ray to screen for lung cancer which may be causing a secondary brain tumour. (CAT), This technique involves taking many x-rays from different angles in a short amount of time. These images are then used to create a three-dimensional image of the brain. This technique is mainly used to rule out other causes of Dementia such as stroke, brain tumor, multiple sclerosis or hemorrhage; Magnetic Resonance Imaging (MRI), This technique uses powerful magnets and radio waves to produce very sharp three-dimensional images of the brain. Currently, MRI is the radiological examination of choice. In addition to ruling out treatable causes of Dementia, MRI can reveal patterns of brain tissue loss that are characteristic of Dementia and can be used to discriminate between different forms of Dementia such as Alzheimer's Disease and Frontotemporal Dementia ; Positron emission tomography (PET) and single photon emission computed tomography (SPECT), in both tests, a small amount of radioactive material is injected into the patient and detectors are placed in the brain to detect the emissions. PET provides visual images of activity in the brain. SPECT is used to measure blood flow to various regions of the brain.

Description of figures

[05] Figure 1 - Illustrates the 3 materials used in the diagnosis of Alzheimer's via saliva: test cassette, which contains the test strip designated for detection of beta-amyloid protein (beta-amyloid 42) with the anti-beta-amyloid antibody , to place the saliva samples mixed with the buffer solution and wait for the result; dropper, used to collect the saliva sample mixed with the buffer solution and place it inside the quick test; Sample tube, which contains an amount of buffer solution to be mixed with the saliva of the individual who will be using the test, has a filling line.

[06] Figure 2-Illustrates the description of the test strip, fundamental material for the method used.

[07] Figure 3 -Illustrates a graph comparing the levels of beta-amyloid in the saliva of people who have and do not have Alzheimer's disease.

Description of the invention

[08] Diagnosis of Alzheimer's via saliva using the lateral flow immunoassay method to detect the beta-amyloid protein (beta-amyloid 42), which presents a greater amount in the stages of the disease. It is detected whether the person has Alzheimer's or not, depending on the result in the test zone, whether it is positive or negative. The individual spits into an open tube until the amount of saliva reaches the fill line, shakes the capped tube (sample tube) for 5-10 seconds to mix the saliva with the buffer solution (Reagent responsible for preventing stickiness and making the liquid flow faster), collect the dilution with the dropper and put it in the quick test, applying 5 drops. , and the components for the control zone. On the nitrocellulose membrane, if the amount of beta-amyloid protein in the saliva is similar to levels of people with Alzheimer's, the test zone (which contains the anti-beta-amyloid) will show a color , if not, it will be absence. The test result will be displayed in the control zone, whether it is valid or not.

Claims (2)

Alzheimer's diagnosis CHARACTERIZED by:

• a) use the lateral flow immunoassay method;
• b) use the saliva of the individual who will be using the test;
• c) have the collection tube containing the buffer solution and the dropper to perform the test; It is
• d) use the dropper to collect the saliva samples mixed with the buffer solution inside the collection tube and then place them inside the quick test.

Alzheimer's diagnosis, according to claim 1, CHARACTERIZED by using the anti-beta-amyloid monoclonal antibody in the test area for detection of the beta-amyloid protein (beta-amyloid 42).

Images